The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) with a history of sino-nasal surgery or for whom surgery is not advisable. This is the first approval for
Similar Posts
FDA Focuses on Closing the Clinical Trial Reporting Gap for Research Integrity
The FDA is committed to ensuring data transparency by promoting timely registration and reporting of results information to ClinicalTrials.gov.Dixon Investments Inc. dba ARI – 710087 – 09/17/2025
CGMP/Finished Pharmaceuticals/AdulteratedCatheter Recall: Medline Industries Removes Reprocessed Electrophysiology and Ultrasound Catheters
Certain reprocessed catheters may contain residual particulates that could cause infection, embolism, or thrombosis.www.d-pharmacy.com – 711075 – 07/16/2025
Unapproved New Drugs/MisbrandedSleep, Skin and Bodybuilding Product Notifications
Learn about the warnings for sleep, skin and bodybuilding products that contain hidden drugs and other hidden ingredients.Wells Pharmacy LLC. Dyersburg, TN. Untitled Letter issued 10/14/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 10/14/2025
Short Title (70 char) Wells Pharmacy LLC. Dyersburg, TN. Untitled Letter issued 10/14/2025
FEI Number 3011761321
Firm Name Wells Pharmacy LLC
Record Type Untitled Letter
State TN
Establishment Type Ou